Skip to main content
    I

    In8bio Inc (INAB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.82
    -0.00 (-0.49%)

    Market Cap: $8.86M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    In8bio Inc (INAB) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    In8bio reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$19.44M, operating cash flow was -$12.71M and free cash flow was -$12.71M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$4.59M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $19.44M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2018 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Cost of revenue$0$0$0$0$0$0$96.00K$96.00K
    Gross profit$0$0$0$0$0$0-$96.00K-$96.00K
    Research and development$10.21M$16.96M$16.83M$14.06M$7.35M$5.38M$2.36M$581.00K
    Operating income-$19.44M-$30.44M-$30.01M-$28.52M-$14.65M-$8.56M-$5.13M-$2.00M
    Net income-$19.44M-$30.44M-$30.01M-$28.52M-$14.65M-$18.90M-$5.13M-$2.08M
    EBITDA-$16.94M-$27.78M-$27.51M-$27.42M-$13.87M-$8.47M-$5.04M-$1.97M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$2.53M$0$0$0$3.75M
    Gross profit$0$0$0-$1.17M$0$0$0-$702.00K$0$0$0$3.12M
    Operating income-$4.59M-$4.78M-$5.09M-$4.94M-$3.85M-$5.09M-$5.55M-$6.16M-$7.09M-$8.63M-$8.56M-$7.60M
    Net income-$4.59M-$4.78M-$5.09M-$4.94M-$3.85M-$5.09M-$5.55M-$6.16M-$7.09M-$8.63M-$8.56M-$7.60M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $1.22M by $25.87M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Total assets$32.28M$20.94M$33.71M$33.04M$42.22M$20.91M$1.13M$5.89M
    Current assets$27.88M$12.58M$24.63M$22.23M$38.98M$18.14M$763.00K$5.07M
    Cash and equivalents$27.09M$11.12M$21.28M$18.18M$37.02M$17.99M$610.00K$4.99M
    Total liabilities$4.72M$6.47M$8.77M$10.31M$4.04M$2.59M$1.48M$1.25M
    Short-term debt$1.22M$0$0$0$0$174.00KN/AN/A
    Shareholder equity$27.56M$14.48M$24.94M$22.73M$38.18M-$16.58M-$346.00K$4.65M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$18.70M$21.75M$26.27M$32.28M$16.77M$19.37M$19.87M$20.94M$15.97M$22.50M$0$33.71M
    Total liabilities$4.52M$3.38M$3.48M$4.72M$3.58M$4.13M$5.99M$6.47M$7.38M$8.88M$0$8.77M
    Cash and equivalents$13.97M$17.96M$21.94M$27.09M$10.69M$13.23M$11.89M$11.12M$4.00M$10.22M$13.02M$21.28M
    Shareholder equity$14.17M$18.36M$22.78M$27.56M$13.19M$15.24M$13.88M$14.48M$8.59M$13.62M$17.53M$24.94M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Operating cash flow-$12.71M-$24.15M-$23.34M-$24.12M-$13.51M-$7.13M-$4.80M-$2.77M
    Capital expenditures$0$104.00K$405.00K$3.69M$0$309.00K$330.00K$757.00K
    Free cash flow-$12.71M-$24.25M-$23.75M-$27.81M-$13.51M-$7.44M-$5.13M-$3.53M
    Share repurchases$0$89.00K$0N/A$2.69M$1.34MN/AN/A
    Investing cash flow$0-$187.00K-$600.00K-$3.71M-$309.00K$0$356.00K-$757.00K
    Financing cash flow$28.64M$14.18M$27.04M$8.99M$32.95M$24.52M$65.00K$8.50M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$3.93M-$3.75M-$4.95M-$2.14M-$3.52M-$3.93M-$3.12M-$4.03M-$6.11M-$6.09M-$7.92M-$4.85M
    Capital expenditures$1.00K$233.00K$9.00K$0$0$0$0$33.00K$83.00K$21.00K$50.00K$2.00K
    Free cash flow-$3.93M-$3.98M-$4.96M-$2.14M-$3.52M-$3.93M-$3.12M-$4.06M-$6.19M-$6.11M-$7.97M-$4.85M
    Last 12 quarters

    Frequently Asked Questions About INAB

    What is In8bio's annual revenue?

    In8bio reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is In8bio profitable?

    No. In8bio reported net income of -$19.44M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does INAB generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$12.71M minus capital expenditures of $0 produced free cash flow of -$12.71M.

    How much debt does In8bio have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $1.22M and cash and equivalents of $27.09M.